At GADx we understand Human, Plant and Animal Health are closely linked and interdependent of the environment we live in. To anticipate and address risk requires an integrated approach to develop and deliver affordable, available and accessible innovative diagnostic approaches which can inform and drive decisions. Whether that be in terms of bio-security, food security, antimicrobial resistance, food safety or climate change. We have expertise in the development through to product delivery for Helminths both in Human and livestock. For livestock see our recent case study https://www.agrialert.co.uk/liver-fluke-test-case-study. Our Centre for Advanced Research Development (funded by BMGF) has enabled biomarker and epitope discovery, antibody engineering with 1pg/ml lateral flow detection sensitivity deploying innovative assay choreography. We continue to push the boundaries of innovation developing both antibody and molecular nucleic lateral flow one-step technologies for human and animal side testing. GADx is keen to support initiatives which support animal health and welfare.

Global Access Diagnostics combining of Mologic's expertise and long history in lateral flow technology and Global Access Health’s reach across a variety of industry and global health sectors, is transforming rapid diagnostics with advanced science and technology. As a pioneering social enterprise in diagnostics, we reinvest all profits to ensure essential tests are affordable and accessible to those most in need. To support these activities, we not only develop and manufacture our own broad product portfolio but take on contractual work, guiding projects from concept to commercial success. Our roots in lateral flow technology trace back to Mologic’s founder, Professor Paul Davis, a pioneer in the field. We excel in molecular science and maintain proficiency across several sectors, including humans, the environment, animals, crops, and aquaculture. Our innovative approach to lateral flow assay choreography and reagent development, coupled with expertise in antibody engineering and regulatory guidance, ensures our c success. We are headquartered in Bedford in the United Kingdom and have a US subsidiary, Mologic Inc. Discover more at www.globalaccessdx.com. GADx partners with Institute Pasteur Dakar (IPD) to support in country LMICs manufacture of test devices. GADx is also committed to reducing the environmental impact of the tests we manufacture. We are collaborating on projects looking at biodegradable materials to be used in manufacturing including recyclable plastics for cassettes housing. To create environmentally sustainable devices from components that are more readily available close to regional manufacturing hubs and that are sustainable, such as plant-based material.